Free for every family. We never ask for money.Questions? hope@mycancertrials.com
Read in:Englishहिन्दीবাংলাमराठीతెలుగుதமிழ்ગુજરાતીاردوಕನ್ನಡଓଡ଼ିଆമലയാളംਪੰਜਾਬੀঅসমীয়াOther languages are in everyday words. The English page is the official one.

Hodgkin lymphoma

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Who can joinAdults
Age18+ years
Kind of studyPhase 4: after approval
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.

Where to go

5 hospitals in India taking patients for this trial.

HCG City Cancer CentreVijayawada, Andhra PradeshDirections ↗
Unique Hospital Multispeciality and Research InstituteSurat, GujaratDirections ↗
HCG Cancer CentreBangalore, KarnatakaDirections ↗
NRS Medical college & Hospital, KolkataKolkata, West BengalDirections ↗
AIIMSNew DelhiDirections ↗
Registry summary (technical)

The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a te…

Sponsor: Takeda
NCT06831370 on ClinicalTrials.gov
Last updated on the registry 23 Feb 2026 · read by us 20 Oct 2026

Need help reaching the trial team? Write to us.

Tell us the city, the type of cancer and the trial number if you have one. We reply in simple words within 3 working days.

ट्रायल टीम से जुड़ने में मदद चाहिए? हमें ईमेल करें।

ట్రయల్ టీమ్‌ను సంప్రదించడానికి సహాయం కావాలా? మాకు ఈమెయిల్ చేయండి.

சோதனைக் குழுவை தொடர்பு கொள்ள உதவி வேண்டுமா? எங்களுக்கு மின்னஞ்சல் செய்யுங்கள்.